Premium
Lithium, long‐acting injectables reduce rehospitalization in bipolar disorder
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30333
Subject(s) - bipolar disorder , lithium (medication) , medicine , treatment of bipolar disorder , cohort , psychiatry , pediatrics , mania
Lithium and long‐acting injectable (LAI) antipsychotics showed the most effective results in preventing rehospitalization in a nationwide cohort study of patients who had been hospitalized for bipolar disorder. The researchers stated that the results support the use of lithium as first‐line treatment for bipolar disorder, with LAIs appearing to be a safe alternative for patients for whom lithium is not a suitable option. Study results were published online Feb. 28 in JAMA Psychiatry .